ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.587,77
-0,52%
S&P 500
5.306,04
0,02%
Dow Jones
38.852,86
-0,55%
Euro vs US Dollar
1,08395
-0,13%
Bitcoin
67.755,64
-0,78%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Nurix Therapeutics Inc (NRIX)

  7. Nurix Therapeutics Inc (NRIX) News

NRIX Nurix Therapeutics Inc

15,54
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:05:14
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Nurix Therapeutics Inc NRIX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 15,54 10:05:14
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
15,54
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
28.5.202413:00GLOBENurix Therapeutics Appoints Paula G. O’Connor, M.D., as..
21.5.202413:06EDGAR2Form 8-K - Current report
21.5.202401:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202401:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.5.202422:00GLOBENurix Therapeutics Announces Board Chair Transition
14.5.202416:00GLOBENurix Therapeutics Announces Upcoming Oral Presentation of..
07.5.202413:00GLOBENurix Therapeutics to Participate in RBC Capital Markets..
17.4.202400:21GLOBENurix Therapeutics Announces Closing of Public Offering and..
12.4.202405:38GLOBENurix Therapeutics Announces Pricing of Upsized $175.0..
11.4.202422:00GLOBENurix Therapeutics Announces Proposed Public Offering
10.4.202413:00GLOBENurix Therapeutics Reports First Quarter Fiscal 2024..
09.4.202419:15GLOBENurix Therapeutics Reports First Clinical Evidence of CNS..
09.4.202413:00GLOBENurix Therapeutics Announces Extension of Strategic..
03.4.202413:00GLOBENurix Therapeutics to Participate in Upcoming Investor..
02.4.202413:00GLOBENurix Therapeutics Announces Extension of Strategic..
25.3.202412:00GLOBENurix Therapeutics is Part of a Team of International..
20.3.202414:40GLOBENurix Presents the Discovery and Chemical Structure of..
11.3.202412:02EDGAR2Form 8-K - Current report
11.3.202412:00GLOBENurix Therapeutics Announces U.S. FDA Lifts Partial Clinical..
06.3.202422:00GLOBENurix Therapeutics to Participate in Upcoming Investor..
05.3.202422:30GLOBENurix Therapeutics Announces Presentations at the American..
17.2.202401:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202422:22EDGAR2Form 144 - Report of proposed sale of securities
15.2.202422:51EDGAR2Form S-8 - Securities to be offered to employees in employee..
15.2.202422:01EDGAR2Form 8-K - Current report
15.2.202422:00GLOBENurix Therapeutics Reports Fourth Quarter and Fiscal Year..
15.2.202413:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202413:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202413:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202414:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01.2.202422:01GLOBENurix Therapeutics Announces Publication in the Journal..
31.1.202400:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.1.202422:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16.1.202422:48DJNNurix Therapeutics Gets FDA Fast-Track Designation for..
16.1.202422:01GLOBENurix Therapeutics Receives U.S. FDA Fast Track Designation..
08.1.202413:03EDGAR2Form 8-K - Current report
08.1.202413:00GLOBENurix Therapeutics Outlines 2024 Strategic Priorities with..
02.1.202422:01GLOBENurix Therapeutics to Present at 42nd Annual J.P. Morgan..
21.12.202323:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.12.202322:19EDGAR2Form 144 - Report of proposed sale of securities
13.12.202322:32GLOBEJudith A. Reinsdorf and Katherine M. Sandstrom Named to Toll..
11.12.202318:03EDGAR2Form 8-K - Current report
11.12.202318:00GLOBENurix Therapeutics Presents Positive Clinical Data from Its..
04.12.202322:01GLOBENurix Therapeutics Announces Webcast To Review Data from Its..
13.11.202313:01EDGAR2Form 8-K - Current report
07.11.202322:01GLOBENurix Therapeutics to Participate in Upcoming Investor..
02.11.202314:00GLOBENurix Therapeutics Announces Presentations at the 65th..

Kürzlich von Ihnen besucht

NASDAQ
NRIX
Nurix Therapeutics
BIT
P1IB84
BNP Paribas Issuance
LSE
XK70
Citi Fun 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten